Document:

Offer Letter with Harvey S. Kanter dated March 2, 2012

 Exhibit 10.1 
 March 2, 2012 
 Mr. Harvey S. Kanter 

1013 Ashlawn Drive 
 Southlake, Texas 76092

 Dear Harvey: 
 I am pleased to
offer you the position of Chief Executive Officer and President of Blue Nile, Inc. (“Blue Nile”) reporting directly to the Board of Directors. Subject to approval by the Board of Directors, you will also be appointed to Blue
Nile’s Board of Directors, with service to commence on your start date, and continued service at the pleasure of Blue Nile’s Board of Directors and stockholders. I look forward to a successful working relationship and to your acceptance of
this offer of employment. 
 Here are the specific terms of your offer: 
 Start Date. March 30, 2012. 
 Base Salary. You will be paid a base salary that
annualizes to $650,000. Your salary will be paid in accordance with Blue Nile’s standard payroll practice and subject to applicable payroll deductions and withholdings. 
 Performance Bonus. You will be eligible to participate in Blue Nile’s 2012 Executive Cash Bonus Plan. Your 2012 annualized target bonus award is 75% of your base salary and can range from 0%
to 200% of target, based on the performance of Blue Nile and your individual performance against key objectives. Your 2012 bonus amount will be prorated based on the number of months you are employed by Blue Nile (employment for a partial month will
be calculated as if employed for the full month) and calculated by reference to the actual salary earned by you during the performance period. 

Stock Options. As we have discussed, equity is an important part of Blue Nile’s compensation program because we believe we will create the
most value for Blue Nile’s shareholders by having employees think and act like owners. Subject to the approval of the Board of Directors or Subcommittee thereof, on your start date (the “Grant Date”), you will be awarded a
non-statutory stock option to purchase 154,500 shares of Blue Nile’s common stock. The exercise price of your stock option will be the closing sales price (or the closing bid, if no sales were reported) as quoted on the NASDAQ National Market
on the last market trading day prior to your Grant Date. Your options will vest over a four year period: one fourth (1/4) of the shares subject to such option will vest on the first year anniversary of your Grant Date and one forty-eighth
(1/48) of the shares subject to such option will vest each month thereafter, in each case as long as your employment continues with Blue Nile. Blue Nile’s 2004 Equity Incentive Plan, the Grant Notice and the Stock Option Agreement
shall govern the terms of this option grant in all respects. The final terms of any stock option granted to you will be determined by the Board of Directors (or its Subcommittee) in its sole discretion. 

Signing Bonus. In appreciation for your decision to join us, along with your first regular paycheck, Blue Nile will pay you a lump sum signing
bonus of $100,000. This signing bonus will be payable in accordance with the Blue Nile’s standard payroll practice and is subject to applicable payroll deductions and withholdings. If you voluntarily leave Blue Nile, or if your employment is
terminated for Cause, in either case prior to the first anniversary of your start date, you will be required to pay back this signing bonus within thirty (30) days of your departure. 
 Relocation. Subject to your relocation to the Seattle area on or before September 30, 2012, Blue Nile will reimburse you for reasonable relocation expenses to cover relocation and temporary
living expenses. You agree to use reasonable efforts to keep the relocation expenses below $100,000. The tax treatment of this payment will be governed by the Internal Revenue Code in effect at the time of relocation. Expenses should be itemized and
submitted on an expense report and accompanied by appropriate receipts. If you voluntarily leave Blue Nile, or if your employment is terminated for Cause, in either case prior to the first anniversary of your start date, you will be required to pay
back your relocation expenses within thirty (30) days of your departure 
 Benefits. You will be eligible to participate in our
standard health care and dental benefits, life and disability insurance, transportation allowance, and a 401(k) plan in accordance with the term and conditions of those plans. Blue Nile reserves the right to review, change, amend, or cancel these
benefits at any time 

 Severance. If prior to a “Change of Control” (as defined in Blue
Nile’s Amended & Restated Change of Control Severance Plan (the “Severance Plan”), you are terminated without “Cause” (and other than as a result of your death or disability), and provided such
termination constitutes a Separation from Service (as defined in the Severance Plan), and provided you sign and return Blue Nile’s standard general waiver and release of all claims and allow such release to become effective not later than the
60th day following your Separation from Service, Blue Nile
will provide you with the following severance benefits (collectively, the “Severance Payment”): 
  

	 	i.	A lump sum cash payment to you in an amount equal to 100% of your then-current annual base salary. This cash payment will be paid in a lump sum on the 60th day after
the date of your Separation from Service, subject to applicable withholdings. 

  

	 	ii.	If you timely elect and remain eligible for continued coverage under COBRA (or any similar state law), the Company will pay you on the first day of each month following
your Separation from Service (except as set forth below), a cash payment equal to the applicable COBRA premiums for that month (including premiums for you and your eligible dependents who have elected and remain enrolled in such COBRA coverage),
subject to applicable tax withholdings (such amount, the “Special Cash Payment”), for a number of months equal to the lesser of (i) the duration of the period in which you and your eligible dependents are eligible for and
enrolled in such COBRA coverage (and not otherwise covered by another employer’s group health plan) and (ii) 12 (12) months. You may, but are not obligated to, use the Special Cash Payment toward the cost of COBRA premiums. If you
become covered under another employer’s group health plan or otherwise cease to be eligible for COBRA during the period provided in this paragraph, you must immediately notify the Company of such event and the Company shall cease payment of the
Special Cash Payments and shall have no further obligations under this paragraph. 

 For purposes of this letter agreement,
termination for “Cause” shall mean any of the following: (i) your conviction of, or guilty plea or plea of nolo contendere to, to a felony under the laws of the United States or of any state, or a crime involving moral
turpitude or dishonesty (including, but not limited to, fraud, theft, or embezzlement); (ii) your participation in any fraud or act of dishonesty against Blue Nile; (iii) your willful misconduct, or your material breach of any agreement
between you and Blue Nile (including, but not limited to, this letter agreement or the Nondisclosure, Proprietary Information, Inventions, Nonsolicitation and Noncompetition Agreement); (iv) conduct that Blue Nile determines, in good faith,
demonstrates unfitness for the job; (v) your engagement in any activity that constitutes a material conflict of interest with Blue Nile; or (vi) your significant failure to perform your duties, gross neglect of your duties, or refusal to
comply with any lawful directive of the Board of Directors, which conduct, if capable of cure or remedy, is not cured or remedied within 30 days following your receipt of written notice from the Board of Directors. 

In addition, subject to approval by the Board of Directors or Subcommittee thereof and your compliance with the terms of the Severance Plan, you will be
eligible to participate in the Severance Plan. Blue Nile reserves the right to review, change, amend, or cancel these benefits at any time. 

Application of Section 409A of the Code. It is intended that all of the benefits provided under this offer letter satisfy, to the greatest
extent possible, the exemptions from the application of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively, “Section 409A”) provided under Treasury
Regulations Sections 1.409A-1(b)(5), and 1.409A-1(b)(9), and this offer letter will be construed to the greatest extent possible as consistent with those provisions. To the extent not so exempt, this offer letter (and any definitions in this offer
letter) will be construed in a manner that complies with Section 409A, and incorporates by reference all required definitions and payment terms. For purposes of Section 409A (including, without limitation, for purposes of Treasury
Regulations Section 1.409A-2(b)(2)(iii)), your right to receive any installment payments under this offer letter will be treated as a right to receive a series of separate payments and, accordingly, each installment payment under this offer
letter will at all times be considered a separate and distinct payment. If Blue Nile determines that any of the payments upon a Separation from Service provided under this offer letter (or under any other arrangement with you) constitute
“deferred compensation” under Section 409A and if you are a “specified employee” of Blue Nile, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, at the time of your Separation from Service, then, solely
to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the payments upon a Separation from Service will be delayed as follows: on the earlier to occur of (i) the date that
is six months and one day after the effective date of your Separation from Service, and (ii) the date of your death (such earlier date, the “Delayed Initial Payment Date”), Blue Nile will (A) pay you a lump sum amount
equal to the sum of the payments upon Separation from Service that you would otherwise have received through the Delayed Initial Payment Date if the commencement of the payments had not been delayed pursuant to this paragraph, and (B) commence
paying the balance of the payments in accordance with the applicable payment schedules set forth above. No interest will be due on any amounts so deferred. If Section 409A is not applicable by law to you, Blue Nile will determine whether any
similar law in your jurisdiction applies and should be taken into account. 

 Standard Agreements. As a condition to your employment, you will be required to sign and comply
with Blue Nile’s standard Nondisclosure, Proprietary Information, Inventions, Nonsolicitation and Noncompetition Agreement relating to the protection of Blue Nile’s proprietary and confidential information and assignment of
inventions. This agreement also restricts your ability to solicit Blue Nile employees or work for a competitor for twelve months after you leave Blue Nile. In addition, you will be required to abide by Blue Nile’s strict policy that
prohibits any new employee from using or bringing with him or her from any previous employer any confidential information, trade secrets, or proprietary materials or processes of such former employer. 

Employee Handbook. As a condition to your employment, you will be required to acknowledge and sign that you have received a copy of Blue
Nile’s Employee Handbook, which includes Blue Nile’s Code of Business Conduct and Ethics and Insider Trading Policy, and that you understand the policies set forth therein. 
 Federal Immigration Law. For purposes of federal immigration law, you will be required to provide to Blue Nile documentary evidence of your identity and eligibility for employment in the United
States. Such documentation must be provided to us within three (3) business days of your date of hire, or our employment relationship with you may be terminated. 
 At-Will Employment. Your employment is at-will, meaning that either you or Blue Nile may terminate the relationship at any time for any reason or for no reason, with or without cause or advance
notice. Any statements to the contrary that may have been made to you, or that may be made to you, are superseded by this offer letter, and this at-will employment relationship cannot be changed except in a writing signed by me. 

Entire Agreement. This offer letter, together with your Employee Nondisclosure, Proprietary Information, Inventions, Nonsolicitation and
Noncompetition Agreement, constitutes the complete and exclusive statement of your employment terms with Blue Nile. The employment terms in this letter supersede any other agreements or promises made to you by anyone, whether written or oral.

 Contingency. This offer is contingent upon the satisfactory results of criminal background, credit, reference and other credential
checks. 
 Harvey, I am excited to welcome you to the Blue Nile team. If you have any questions, please contact me. 

 

	
	Warm Regards,
	
	/s/ Mark Vadon
	
	Mark Vadon
	Chairman of the Board of Directors

 Please indicate your acceptance by signing and returning this letter.

 

					
	Signed:    	 	
/s/    Harvey Kanter             
       
	 	        Dated: 3/4/12
		 	Harvey S. KanterAmendment No.1 to the Employment Agreement

 Exhibit 10.1 
 AMENDMENT TO EMPLOYMENT AGREEMENT 
 THIS AMENDMENT (this
“Amendment”) to that certain Employment Agreement (the “Employment Agreement”), effective as of September 7, 2011, by and between Philip C. Ranker (the “Executive”) and Marina Biotech, Inc., a
Delaware corporation (the “Company”), is made effective as of March 7, 2012. 
 WHEREAS, the Company and
the Executive entered into the Employment Agreement to set forth the terms of the Executive’s employment by the Company during an Employment Period commencing on September 7, 2011 and terminating at the close of business on March 7,
2012; and 
 WHEREAS, the Company and the Executive desire to amend the Employment Agreement, pursuant to Section 22 of the
Employment Agreement, to, among other things described in this Amendment, extend the Employment Period to September 7, 2012. 
 NOW, THEREFORE, in consideration of the mutual covenants contained in this Amendment and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company
and the Executive hereby agree as follows: 
  

	 	1.	Section 3 of the Employment Agreement is hereby deleted in its entirety and replaced in its entirety with the following: “Term; Employment Period. The
“Employment Period” under this Agreement shall commence on the Effective Date and shall terminate at the close of business on September 7, 2012 unless it is (a) extended by written agreement between the parties or
(b) earlier terminated pursuant to Section 10 hereof.” 

  

	 	2.	In connection with the extension of the Employment Period as described in Section 1 of this Amendment, the reference to “March 7, 2012” in clause
(iv) of Section 10(d) of the Employment Agreement is hereby amended to be a reference to “September 7, 2012”. In addition, the third sentence of Section 7 of the Employment Agreement is hereby deleted in its entirety and
replaced in its entirety with the following: “The Company shall reimburse Executive for reasonable travel expenses to and from Executive’s home residence in San Diego, CA to and from Bothell, WA until the expiration of the Employment
Period.” 

  

	 	3.	 The first parenthetical in each of Section 17(b) and Section 17(d) of the Employment Agreement is hereby deleted in its entirety and replaced
in its entirety with the following: “(and only if the Executive’s employment is terminated by the Company for Cause)”. In addition, the reference to “twelve (12) months” in Section 17(c) of the Employment Agreement
is 

	 	
hereby replaced by a reference to “six (6) months”, and the references to “collaborative partners, consultants, certified research organizations, principal vendors and
licensees” in Section 17(c) of the Employment Agreement are hereby deleted in their entirety. 

 For
purposes of the Employment Agreement and this Amendment, any reference to “directly competitive” means a company, product, activity, or any other aspect of the industry that may be subject to limitations as set forth in the aforementioned
agreements that are, in their entirety, nucleic acid-based or pertaining to the delivery or other aspect of a nucleic acid-based therapeutic. For the avoidance of doubt, if the Company were to develop a cardiovascular therapeutic, a company,
product, activity, or other aspect of the industry would only be considered directly competitive if it involves a nucleic acid-based therapeutic exclusively. All other cardiovascular research and development or commercial efforts would not be
considered directly competitive. 
  

	 	4.	Except as otherwise expressly provided by this Amendment, all of the terms and conditions of the Employment Agreement are, and shall continue to be, in full force and
effect and are hereby ratified and confirmed in all respects. 

  

	 	5.	Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Employment Agreement. 

 

	 	6.	This Amendment shall be construed in accordance with and governed for all purposes by the laws of the State of Washington applicable to contracts made and to be
performed wholly within such State, without regard to the principles of conflicts of laws thereof. 

  

	 	7.	This Amendment may be executed in two or more counterparts, each of which shall be considered one and the same amendment and shall become effective when counterparts
have been signed by each party and delivered to the other party. In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed signature page, such
signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof. 

 

	 	8.	This Amendment shall be effective upon the Company’s execution and receipt of the same amendment executed by the Executive. 

[remainder of page intentionally left blank; signature page follows] 

  
 2 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by their
respective authorized signatures as of the date first set forth above. 
  

			
	 MARINA BIOTECH, INC.

		
	 By:
	 	 /s/ J. Michael French

	 Name:
	 	     J. Michael French
	 Title:
	 	     President and Chief Executive Officer
	 Date:
	 	     March 16, 2012

  

			
	 /s/ Philip C. Ranker

	 Name:
	 	Philip C. Ranker
	 Date:
	 	March 12, 2012

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]